Crescent Biopharma, Inc.
CBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $20,347 | $12,081 | $15 | $233 |
| G&A Expenses | $5,538 | $8,949 | $2,384 | $5,081 |
| SG&A Expenses | $5,538 | $8,949 | $2,384 | $5,081 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $2,019 |
| Operating Expenses | $25,885 | $21,030 | $2,399 | $7,333 |
| Operating Income | -$25,885 | -$21,030 | -$2,399 | -$7,333 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,278 | -$760 | $55 | $111 |
| Pre-Tax Income | -$24,607 | -$21,790 | -$2,344 | -$7,222 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24,607 | -$21,790 | -$2,344 | -$7,223 |
| % Margin | – | – | – | – |
| EPS | -1,266.44 | -0.56 | -0.036 | -0.11 |
| % Growth | -226,050% | -1,442.7% | 67% | – |
| EPS Diluted | -1,266.44 | -0.56 | -0.036 | -0.11 |
| Weighted Avg Shares Out | 165,408 | 38,569 | 64,522 | 64,484 |
| Weighted Avg Shares Out Dil | 165,408 | 38,569 | 64,522 | 64,484 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,278 | $313 | $55 | $110 |
| Interest Expense | $0 | $1,073 | $0 | $0 |
| Depreciation & Amortization | $28 | $0 | $0 | $0 |
| EBITDA | -$24,579 | -$20,717 | -$2,399 | -$5,314 |
| % Margin | – | – | – | – |